Structure–Activity‐Related Analysis of ACE Inhibitory Peptides Against Furin: A Dual‐Action Therapeutic Approach Against SARS‐CoV‐2

Fuente: Wiley Open Access
Salvato in:
Dettagli Bibliografici
Autori principali: Ainolsyakira Mohd Rodhi, Pei‐Gee Yap, Chee‐Yuen Gan
Natura: Artículo Open Access
Pubblicazione: Wiley 2025
Soggetti:
Accesso online:
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
_version_ 1867004740727996416
author Ainolsyakira Mohd Rodhi
Pei‐Gee Yap
Chee‐Yuen Gan
author_facet Ainolsyakira Mohd Rodhi
Pei‐Gee Yap
Chee‐Yuen Gan
Ainolsyakira Mohd Rodhi
Pei‐Gee Yap
Chee‐Yuen Gan
collection Wiley Open Access
contents Structure–Activity‐Related Analysis of ACE Inhibitory Peptides Against Furin: A Dual‐Action Therapeutic Approach Against SARS‐CoV‐2 Ainolsyakira Mohd Rodhi Pei‐Gee Yap Chee‐Yuen Gan Peptide Science ABSTRACT The severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), which is responsible for the COVID‐19 pandemic, enters host cells by binding its spike protein to the angiotensin‐converting enzyme 2 (ACE) receptor on the surface of lung endothelial cells. ACE inhibitors, which were used to manage hypertension, have shown potential to interfere with this viral entry mechanism. This study investigates the dual inhibitory potential of ACE inhibitory peptides against furin, an essential enzyme for the activation of the SARS‐CoV‐2 spike protein. A molecular docking study was performed to identify key interacting amino acid residues at the N‐ and C‐termini that stabilize peptide–furin interactions. Key residues, including ARG, LYS, ALA, and VAL, along with the hydrophobic amino acids PRO, GLY, and LEU, play significant roles in stabilizing these interactions via hydrophobic forces. These residues enhance peptide–enzyme affinity by contributing structural rigidity and flexibility, optimizing binding orientation. The analysis revealed that most ACE inhibitory peptides engage in noncompetitive inhibition by binding to an allosteric site on furin, composed of key residues, such as GLU271, GLY307, SER311, TYR313, LYS449, GLN488, ARG490, ASP530, and ALA532. In vitro and in vivo studies are necessary to further evaluate the therapeutic safety and efficacy of these peptides, paving the way for innovative treatment strategies against COVID‐19. 10.1002/pep2.70013 http://onlinelibrary.wiley.com/termsAndConditions#vor
doi_str_mv 10.1002/pep2.70013
format Artículo Open Access
id wiley_oa_10_1002_pep2_70013
institution Wiley Open Access
license_str_mv http://onlinelibrary.wiley.com/termsAndConditions#vor
publishDate 2025
publisher Wiley
record_format wiley_oa
spellingShingle Structure–Activity‐Related Analysis of ACE Inhibitory Peptides Against Furin: A Dual‐Action Therapeutic Approach Against SARS‐CoV‐2
Ainolsyakira Mohd Rodhi
Pei‐Gee Yap
Chee‐Yuen Gan
Peptide Science
Structure–Activity‐Related Analysis of ACE Inhibitory Peptides Against Furin: A Dual‐Action Therapeutic Approach Against SARS‐CoV‐2 Ainolsyakira Mohd Rodhi Pei‐Gee Yap Chee‐Yuen Gan Peptide Science ABSTRACT The severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), which is responsible for the COVID‐19 pandemic, enters host cells by binding its spike protein to the angiotensin‐converting enzyme 2 (ACE) receptor on the surface of lung endothelial cells. ACE inhibitors, which were used to manage hypertension, have shown potential to interfere with this viral entry mechanism. This study investigates the dual inhibitory potential of ACE inhibitory peptides against furin, an essential enzyme for the activation of the SARS‐CoV‐2 spike protein. A molecular docking study was performed to identify key interacting amino acid residues at the N‐ and C‐termini that stabilize peptide–furin interactions. Key residues, including ARG, LYS, ALA, and VAL, along with the hydrophobic amino acids PRO, GLY, and LEU, play significant roles in stabilizing these interactions via hydrophobic forces. These residues enhance peptide–enzyme affinity by contributing structural rigidity and flexibility, optimizing binding orientation. The analysis revealed that most ACE inhibitory peptides engage in noncompetitive inhibition by binding to an allosteric site on furin, composed of key residues, such as GLU271, GLY307, SER311, TYR313, LYS449, GLN488, ARG490, ASP530, and ALA532. In vitro and in vivo studies are necessary to further evaluate the therapeutic safety and efficacy of these peptides, paving the way for innovative treatment strategies against COVID‐19. 10.1002/pep2.70013 http://onlinelibrary.wiley.com/termsAndConditions#vor
title Structure–Activity‐Related Analysis of ACE Inhibitory Peptides Against Furin: A Dual‐Action Therapeutic Approach Against SARS‐CoV‐2
topic Peptide Science
url https://onlinelibrary.wiley.com/doi/10.1002/pep2.70013